Global Intravenous Immunoglobulin (IVIG) Market Size, Share, Growth, Trends, Company Analysis and Forecast 2019-2026

Section 1: INTRODUCTION

1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.4. Research methodology

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

Section 2: EXECUTIVE SUMMARY

2.1. CXO perspective

Section 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Overview of Immunoglobulin

3.2.1. Patented products
3.2.2. Epidemiology and economic burden of chronic conditions

3.3. Key findings

3.3.1. Top Investment Pockets

3.4. Porter’s five forces analysis
3.5. Value chain analysis

3.5.1. Primary activities
3.5.2. Support activities

3.6. Market share analysis, 2017
3.7. Product scenario in intravenous immunoglobulin market
3.8. Government regulations and reimbursements

3.8.1. U.S.
3.8.2. Europe
3.8.3. France
3.8.4. Germany
3.8.5. Italy
3.8.6. China
3.8.7. Japan
3.8.8. India

3.9. Indications for immunoglobulin

3.9.1. U.S. FDA indications
3.9.2. EMA

3.10. Component analysis of immunoglobulin G (IgG)

3.10.1. IgG1
3.10.2. IgG2
3.10.3. IgG3
3.10.4. IgG4

3.11. Market dynamics

3.11.1. Drivers

3.11.1.1. Rise in prevalence of immunodeficiency diseases
3.11.1.2. Increase in adoption of immunoglobulin treatment
3.11.1.3. Growth in incidence of bleeding disorders

3.11.2. Restraints

3.11.2.1. Stringent government regulations
3.11.2.2. High cost of therapy

3.11.3. Opportunities

3.11.3.1. Opportunities in emerging economies
3.11.3.2. Development of cost-effective therapeutics through large-scale production

Section 4: IMMUNOGLOBULIN MARKET, BY APPLICATION

4.1. Overview

4.1.1. Market size and forecast

4.2. Hypogammaglobulinemia

4.2.1. Market size and forecast

4.3. Chronic Inflammatory demyelinating polyneuropathy (CIDP)

4.3.1. Market size and forecast

4.4. Primary immunodeficiency diseases

4.4.1. Market size and forecast

4.5. Myasthenia Gravis

4.5.1. Market size and forecast

4.6. Multifocal motor neuropathy

4.6.1. Market size and forecast

4.7. Idiopathic thrombocytopenic purpura (ITP)

4.7.1. Market size and forecast

4.8. Inflammatory myopathies

4.8.1. Market size and forecast

4.9. Specific antibody deficiency

4.9.1. Market size and forecast

4.10. Guillain-Barre syndrome

4.10.1. Market size and forecast

4.11. Others

4.11.1. Market size and forecast

Section 5: IMMUNOGLOBULIN MARKET, BY PRODUCT

5.1. Overview

5.1.1. IGG

5.1.1.1. Key market trends

5.1.2. Clinical interpretations
5.1.3. IGA

5.1.3.1. Key Market Trends

5.1.4. Clinical interpretation
5.1.5. IGM

5.1.5.1. Key Market Trends

5.1.6. Clinical interpretation
5.1.7. IGE

5.1.7.1. Key Market Trend

5.1.8. Clinical interpretation
5.1.9. IGD

5.1.9.1. Key Market Trends

5.1.10. Clinical interpretation

Section 6: INTRVAENOUS IMMUNOGLOBULIN MARKET, BY REGION

6.1. Overview

6.1.1. Market size and forecast

6.2. North America

6.2.1. Key trends and opportunities
6.2.2. North America market size & forecast, by application
6.2.3. North America market size & forecast, by country

6.2.3.1. U.S. market size & forecast
6.2.3.2. Canada market size & forecast
6.2.3.3. Mexico market size & forecast

6.3. Europe

6.3.1. Key trends and opportunities
6.3.2. Europe market size & forecast, by application
6.3.3. Europe market size & forecast for immunoglobulin market, by country

6.3.3.1. Germany market size & forecast
6.3.3.2. France market size & forecast
6.3.3.3. UK market size & forecast
6.3.3.4. Italy market size & forecast
6.3.3.5. Austria market size & forecast
6.3.3.6. Russia market size & forecast
6.3.3.7. Rest of Europe market size & forecast

6.4. Asia-Pacific

6.4.1. Key trends and opportunities
6.4.2. Asia-Pacific market size & forecast, by application
6.4.3. Asia-Pacific market size & forecast, by country

6.4.3.1. Australia market size & forecast
6.4.3.2. China market size & forecast
6.4.3.3. India market size & forecast
6.4.3.4. Japan market size & forecast
6.4.3.5. Rest of Asia-Pacific market size & forecast

6.5. LAMEA

6.5.1. Key trends and opportunities
6.5.2. LAMEA market size & forecast, by application
6.5.3. LAMEA market size & forecast, by country

6.5.3.1. Brazil market size & forecast
6.5.3.2. Saudi Arabia market size & forecast
6.5.3.3. Argentina market size & forecast
6.5.3.4. Turkey market size & forecast
6.5.3.5. Rest of LAMEA market size & forecast

Section 7: COMPANY PROFILES

7.1. BAXTER INTERNATIONAL INC.

7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product portfolio
7.1.5. Business performance
7.1.6. Key strategic moves and developments

7.2. BAYER AG

7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product portfolio
7.2.5. Business performance
7.2.6. Key strategic moves and developments

7.3. BIOTEST AG

7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Product portfolio
7.3.5. Business performance

7.4. CHINA BIOLOGIC PRODUCTS, INC.

7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product portfolio
7.4.5. Business performance

7.5. CSL LIMITED

7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product portfolio
7.5.5. Business performance

7.6. GRIFOLS S.A.

7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product portfolio
7.6.5. Business performance
7.6.6. Key strategic moves and developments

7.7. KEDRION BIOPHARMA INC.

7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product portfolio
7.7.5. Business performance
7.7.6. Key strategic moves and developments

7.8. LFB SA (LFB BIOTECHNOLOGIES SAS)

7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product portfolio
7.8.5. Business performance

7.9. OCTAPHARMA AG

7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product portfolio
7.9.5. Business performance

7.10. TAKEDA PHARMACEUTICAL COMPANY LIMITED

7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Product portfolio
7.10.5. Business performance
7.10.6. Key strategic moves and developments